Added to YB: 2026-02-26
Pitch date: 2026-02-24
NVO [neutral]
Novo Nordisk A/S
-2.09%
current return
Author Info
HatedMoats identifies hated moats. I buy companies when the market panics. Contrarian investor focused on quality, value & long-term growth. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 243.50
Price Target
N/A
Dividend
4.65%
EV/EBITDA
7.88
P/E
10.92
EV/Sales
3.95
Sector
Pharmaceuticals
Category
turnaround
What's going on with Novo Nordisk?
NVO (trimmed via covered calls): CagriSema missed non-inferiority vs tirzepatide in REDEFINE 4—23.0% weight loss vs 25.5% at week 84. Failed primary endpoint that was supposed to establish parity with Lilly. Higher-dose trial planned H2 2026, FDA decision late 2026. Selling covered calls to mitigate near-term underperformance; will consider exit by late 2026 if no turnaround.
Read full article (7 min)